About Us

Osmol Therapeutics is a clinical stage company advancing a first-in-class preventative treatment for chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI), debilitating conditions that can significantly impact both quality of life and survival.

Leadership Team

Bob Linke, MBA
President & CEO

Barbara Ehrlich, PhD
Chief Scientific Advisor

Ron Weitzman, MD, FACP
Chief Medical Officer

Julie Straub, PhD
VP, Preclinical Development & CMC

Ann Robbins, PhD
VP, Regulatory Affairs

Gary Connor, RN
VP, Clinical Development

Board of Directors